Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.
Yimin WangHedong HanFang ZhangTangfeng LvPing ZhanMingxiang YeYong SongHongbing LiuPublished in: British journal of cancer (2022)
In conclusion, for non-squamous NSCLC patients, accepting PD-1 as the first-line treatment may be a relatively better option.